Patent classifications
G01N33/5026
DEVICE AND METHOD FOR FORCE PHENOTYPING OF CELLS FOR HIGH-THROUGHPUT SCREENING AND ANALYSIS
A system for assaying forces applied by cells includes an optically transparent substrate comprising a soft material having a Young's modulus within the range of about 3 kPa to about 100 kPa. An array of molecular patterns is disposed on a surface of the optically transparent substrate, the molecular patterns include fluorophore-conjugated patterns adherent to cells. The system includes at least one light source configured to excite the fluorophore-conjugated patterns and an imaging device configured to capture fluorescent light emitted from the fluorophore-conjugated patterns. Dimensional changes in the size of the patterns are used to determine contractile forces imparted by cells located on the patterns.
CELL SCANNING TECHNOLOGIES AND METHODS OF USE THEREOF
Diagnostic and screening technologies, therapy recommendations, and computer systems based on red blood cell membrane permeability characteristics are provided herein.
ANTI-ICOS ANTIBODIES
Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
System and methods for in vitro structural toxicity testing
A system and process use artificial intelligence to evaluate the toxicity of drugs on cells. In some embodiments, a convolutional neural network is trained to identify features in cells and thereafter identify when structural changes in cells are signs of damage from exposure to a drug. Some embodiments use a 2-class deep neural network, comparing drug-treated cells to controls, to learn which images may show signs of toxicity as a result of the drug. In some applications, the system may capture images from a time-lapse experiment to determine from the cell cultures how a drug affects a cell type over time.
Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program
A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.
Lymphocyte-based morphometric test for alzheimer's disease
This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
Chip platforms for microarray 3D bioprinting
A micropillar and microwell chip and methods of studying cellular environments using micropillar and microwell chips is disclosed. The micropillar chip may include at least one micropillar with a pillar-microwell. The microwell chip may include at least one microwell with an upper and a lower microwell. A perfusion channel chip that may be integrated with a micropillar chip is also disclosed. The perfusion channel chip may include a channel, a pillar-insertion hole, a membrane cassette, and a reservoir well.
COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION
Disclosed are methods of modulating macrophage activation to treat various diseases, such as cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases. Also disclosed are methods of identifying compounds useful for modulating macrophage activation as means to treat cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases.
ORGANOTYPIC DRG-PERIPHERAL NERVE CULTURE SYSTEM
Techniques and systems are disclosed for a bioassay that is an in vitro mimic of peripheral nerve generation using the sensory neurons that innervate the peripheral nervous system. In some embodiments, the techniques may assist in detecting the bioactivity or potency of nerve grafts (e.g., processed, acellular human allografts) for fostering or supporting peripheral nerve regeneration. In various embodiments, techniques comprise affixing a harvested sensory neuron (e.g., a DRG) to a nerve graft segment to form a test construct; culturing the test construct in a medium; analyzing the test construct to indicate the amount of outgrowing peripheral nerve structure; and determining the potency of the nerve graft from a metric derived from the analysis. In some embodiments, techniques and materials may be used to test the effect of a varied test condition on peripheral nerve growth.
RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL
The invention relates to an assay for diagnosing a disease or affliction that affects fluid uptake or secretion or for studying the effectiveness of one or more drugs for treating the disease or affliction, wherein the assay comprises measuring swelling of one or more organoids.